Don't miss out! Join us next Wednesday, 3/18, for the Philadelphia Drug Discovery Forum! Join Mallika Singh, Ph.D., of Revolution Medicines for her talk, “Targeting the Oncogenic State of RAS.” 🕞 Doors open: 3:30 PM 🕓 Talk begins promptly: 4 PM 🥂 Networking: 5 PM 👉 Register now! bit.ly/4qQkg6B

Wistar scientists have developed a vaccine strategy that induced neutralizing antibodies with a single shot in a preclinical study—a first-ever achievement. Led by Dr. Amelia Escolano, this breakthrough could lead to simpler, faster, and cheaper vaccination protocols globally. bit.ly/4ceGGdY

Thanks to our speakers Dr. Jason DeHart and Dr. Jason Lamontagne and everyone who joined the latest Philadelphia Drug Discovery Forum! Want to connect with Philly’s biopharma community? Join the next PDDF on March 18, 4–6 p.m. Learn more: bit.ly/4bcdm7B

🚨 Last chance to register! Join us Jan 21, 4–6 p.m. at The Wistar Institute for the Philadelphia Drug Discovery Forum. Hear from leaders in biopharma and connect with peers shaping the future of medicine. Register: bit.ly/4hQgasj

Congrats to Dr. Italo Tempera on his promotion to Professor! After postdoc training in Wistar's Lieberman lab, he launched his own lab at Temple before returning to Wistar in 2020. Since then, he's published in top‑tier journals and had major grant success. 👏 Congrats! bit.ly/49mwnTv

Hear from Federica Severi, a pre-doctoral trainee in Dr. Dan Claiborne's lab, about her work researching CAR T cells as a therapy against HIV. “What we do here is immunotherapy, where we make the immune system more powerful against infection … like HIV”

Hear from Wistar predoctoral fellow Maya Foster about what fuels her passion for science. "I work with actual cancer cells -- we do actual cancer research. Our work is quite important."

Wistar was proud to host Life Science Cares Philadelphia for a tour! As a valued partner, they support our work to expand access to life science careers for those in HS, college and beyond.

The American Society of Gene + Cell Therapy Annual Meeting was an amazing opportunity for Wistar scientists Drs. Patel, Gary and Parzych, & predoc Nick Tursi, in the lab of Dr. David Weiner, to share their important research on such a huge stage!

We’re excited to welcome Dr. Xiaoyu Zhou as assistant professor in Wistar’s Vaccine & Immunotherapy Center! Her cutting-edge work in immune cell communication & CAR T-cell engineering is a great addition to Wistar’s collaborative work advancing cancer & infectious disease therapies. bit.ly/4iLDypU

In a new collaborative paper from Wistar’s Salvino lab, the Penn Perelman School of Medicine, and the University of Leeds, published in Nature Structural & Molecular Biology, researchers have discovered a new molecular glue that combats dysregulated inflammatory signaling: bit.ly/4lf941M

Three Wistar trainees were recently recognized for excellence in science. Dr. Ignacio Rodriguez Relano received the 2024 Ching Jer Chern Postdoctoral Fellowship, while Drs. Phillip Wulfridge & Brennah Murphy Britten received the 2024 & 2025 Ching Jer Chern Memorial Awards. Congratulations!

Thanks to the Justamere Foundation for awarding Wistar’s Hubert J.P. Schoemaker Education and Training Center a 2-year, $150K grant. The grant supports Wistar’s BTT for ALL in PHL Program that helps residents of Philadelphia train for secure jobs in the region’s thriving biomedical sector.

On World TB Day, we shine a light on the deadliest infectious disease in the world. Caused by Mycobacterium tuberculosis, it has been around for centuries and has been tracked in the U.S. since the 1950s. Learn more about this disease and why it’s making a resurgence now: bit.ly/4iAX6ho

Wistar recently unveiled 2 new internal grants that will provide valuable funding opportunities to early-career researchers to foster collaborations & eventually establish independent research programs: bit.ly/4bV9zK8

Wistar's Dr. Kristy Shuda McGuire strongly believes, “To learn science, you need to do science.” She comes from a long line of teachers & has her hand on the pulse of the latest training needed for next-gen science careers. Learn more: bit.ly/4iJaDD6

Triple-negative breast cancer is a difficult-to-treat cancer that affects 10-15% of breast cancer patients in the U.S., defined by the absence of 3 receptors: estrogen, progesterone, and HER2. Continued cancer research is essential to overcoming this challenge. #triplenegativebreastcancerday

Wistar is pleased to announce the recruitment of its newest faculty member, Dr. Colby Maldini, to the HIV Cure and Viral Diseases Center. The Maldini lab will expand his work on CAR T cells as part of a strategy to cure HIV and other viral threats. bit.ly/4gWzcv2

New preclinical research from Wistar’s @filippov81.bsky.social published in Cancer Discovery shows how brain cancer reprograms immune cells to work for the cancer rather than against it. Their discovery also enables a potential treatment to disrupt the reprogramming process. bit.ly/4ijBIMT

The Wistar Institute's Montaner lab was pleased to host members of the HIV Advocacy for Cure Academy, who received a tour of the Institute and Dr. Montaner's laboratory facilities where scientists continue their work to seek a cure for HIV.

Some questions Wistar's EHS head Roma Maraj-Owens thinks about a lot: “What are your experimental procedures? How can we protect our employees and the environment?” Read more about how she ensures institutional safety in her Q&A: bit.ly/41lh0FP

In their second “Top Read” paper in less than a year, Wistar’s Montaner lab has published the successful preclinical results of their new anti-HIV approach: NuKES, or Natural Killer Enhancement Strategy, which targets the viral reservoirs standing in the way of a cure. bit.ly/4hF0UNZ

Many thanks to @jenheemstra.bsky.social of Washington University in St. Louis for joining The Wistar Institute as part of the Distinguished Lectures in Cancer Research series, to speak to the importance of intentional, high-quality mentorship in the sciences. Read more: bit.ly/41ao9d3

In a new paper, Wistar’s Villanueva lab has discovered a new strategy to treat melanomas harboring mutations in the NRAS gene that don’t respond to MAPK inhibitors. Their treatment kills these mutant melanoma cells in preclinical testing with FDA-approved drugs. Our story: bit.ly/411yfwB

Wistar is hiring! Friday 2/7, join us at Temple University's job fair from 11-2 pm at the Howard Gittis Student Center to learn about our openings for postdoctoral fellowships and research assistant roles throughout more than 30 labs. Hope to see you there! No registration required.

Thanks to a new research grant from the Melanoma Research Foundation, The Wistar Institute’s Dr. Kazuko Nishikura is embarking on a project she hopes will serve as a proof of concept for a cancer treatment decades in the making. Our story: bit.ly/3WKOtYs

Every cancer case starts somewhere, While new treatments are vital, prevention is just as key to protecting health. That’s why researchers at Wistar’s Ellen and Ronald Caplan Cancer Center pursue research to detect risks early & stop cancer in its tracks. #nationalcancerpreventionmonth

Education and Training Center is expanding our job-training programs for PA science careers with a new Quality Science Pathway Apprenticeship Program and further investment in existing programs. Read more: bit.ly/4jD3Fkb

Wistar welcomed the Greater Philadelphia Chapter of the Association of Fundraising Professionals for its 2025 Annual Meeting. Members heard the association’s vision for the upcoming year and took time to network & discuss best practices in donor stewardship.

Philadelphia has one of the most punctual airports in the world, so it's easy to travel to and from The Wistar Institute. Whether you’re heading to a conference, a collaboration, or returning from a visit back home, you’ll get to your destination on time. #WorkAtWistar

In collaboration, The Wistar Institute and Stanford University researchers report results from a first-in-human clinical trial testing a novel investigational drug for cancers associated with the ubiquitous Epstein-Barr Virus (EBV). Our story: bit.ly/3WsbxLC

Congratulations to Wistar Executive Vice President Luis Montaner, whom @immunologyaai.bsky.social has recognized with their highest honor of Distinguished Fellow. The 2025 Fellows are honored for "outstanding scientific contributions as well as their service to... the immunology community."

Wistar’s collaborations with Penn, Philadelphia College of Osteopathic Medicine, and University of Bologna allow PhD students to pursue research at Wistar, where leading experts train, guide, and mentor students on their research-career journeys. bit.ly/41ZpEeV #nationalmentoringmonth

This #NationalTriviaDay, test yourself against The Wistar Institute Trainee Association in a round of trivia, with topics covering everything from The Wistar Institute to biology to the great city of Philadelphia: bit.ly/3BUsneY #trivia

The Wistar Institute has been named one of the world’s top 1000 companies in a new ranking from @newsweek.com’s Excellence Index 2025, which recognized Wistar for “leading the way” in its sector. Wistar ranked first among Pennsylvanian companies. bit.ly/3VRIosV

@councilmemberjg.bsky.social visited Wistar, toured the Montaner #HIV research lab, & discussed our education & training programs that are committed to building a Philadelphia workforce for science careers needed now. #STEMcareertraining #STEMapprenticeships

We sat down with Dr. Dan Claiborne to learn more about how his research in CAR T cells will support the emboldened HIV research mission at Wistar through the new HIV Cure and Viral Diseases Center. Read our story here: bit.ly/3VLOtab

Thanks to support from The V Foundation, Drs. Nan Zhang and Noam Auslander have been named as V Scholars and awarded $1.2 million in grant funding to support research that aims to improve existing cancer therapies. Our story: bit.ly/4gudEpE

Wistar in the news: thanks to Inside Precision Medicine for their story on the latest research from The Wistar Institute's Weiner lab, the first-ever trispecific T cell engager for treating glioblastoma. The approach significantly enhanced survival in preclinical testing. bit.ly/3BsLBbj

Wistar’s Communications & Marketing Team was honored with a Pepperpot Award for its external newsletter, The Wistar News. The award, started in 1968 to recognize excellence in communications & public relations, is named after a beloved Philly Campbell’s soup. www.wistar.org/news-sign-up/

Wistar’s Dr. Rahul Shinde studies new potential therapies for treatment resistant cancers like pancreatic cancer. Learn more about his lab’s work, and how diet and the gut microbiome may affect cancer risk, in the latest edition of Wistar Science Update: bit.ly/3CYohTb

New research: Scientists at The Wistar Institute’s Vaccine & Immunotherapy Center, led by EVP Dr. David Weiner, have designed and tested a novel immunotherapy for glioblastoma that counters the cancer’s treatment resistance and increases survival in preclinical lab testing. bit.ly/3CTrW4G